Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy-Reference-Cited by-同舟云学术

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

Published:2020-06 Issue:8 Volume:9 Page:537-551
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Gilbert Lucy¹²³,Ramanakumar Agnihotram V⁴,Festa Maria Carolina¹²,Jardon Kris¹²³,Zeng Xing¹²³,Martins Claudia¹²³,Shbat Layla¹²,Alsoud Marwa Abo¹²,Borod Manuel³⁵,Wolfson Michael⁶,Papaioannou Ioanna⁷,Basso Olga⁴⁸^ORCID,Sampalis John⁷⁹^ORCID

Affiliation:

1. McGill University Health Center, Gynecologic Cancer Services, Cancer Care Mission, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada

2. McGill University, Department of Obstetrics & Gynecology, 1001 Decarie Boulevard, Montreal, QC, H4A 3 J1, Canada

3. Department of Oncology, McGill University, 5100 de Maisonneuve Boulevard West, Montreal, QC, H4A 3T2, Canada

4. Research Institute of The McGill University Health Center, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada

5. McGill University Health Center, Supportive & Palliative Care Services, Cancer Care Mission, 1001 Decarie Boulevard, Montreal, QC, H4A 3 J1, Canada

6. University of Ottawa, Department of Epidemiology & Community Medicine, 600 Peter Morand Crescent, Ottawa, Canada, K1G 5Z3, Canada

7. JSS Medical Research, 9400 Henri-Bourassa West, Montreal, QC, H4S 1N8, Canada

8. Department of Epidemiology, Biostatistics, & Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada

9. McGill University, Faculty of Medicine, Department of Surgery, Division of Surgical Research, 1650 Cedar Avenue, Montreal, QC, H3G 1A4, Canada

Abstract

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0032

Reference24 articles.

1. Cancer statistics, 2017

2. Projections of the Cost of Cancer Care in the United States: 2010-2020

3. Treatment of recurrent ovarian cancer

4. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?;Current Oncology;2023-04-07

2. Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada;Current Oncology;2022-09-30

3. Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data;Journal of Health Economics and Outcomes Research;2021-12-09

4. Cytotoxic chemotherapy increases costs but not survival in recurrent ovarian cancer in Canada;PharmacoEconomics & Outcomes News;2020-04